There is strong evidence showing that silencing of FTO can suppress tumor growth, potentiate immune-promoting response, and attenuate drug resistance, thereby highlighting the bright prospect of targeting FTO in cancer treatment (Li et al., 2022). This evidence concerns the gene FTO and cancer.